Trends in pharma deals — a BioCentury podcast

Plus: FDA signals flexibility with Precigen decision, and Denali tech among other translational highlights 

BioCentury’s third annual analysis of pharma company deals finds that bispecifics and degraders are in, cell and gene therapies are out, and China is bringing much more than me-too assets to cross-border deals. On the latest BioCentury This Week podcast, BioCentury’s analysts assess a year’s worth of deals between pharmas and biotechs to tease out emerging trends.

The analysts also discuss last week’s FDA approval of a vector-based immunotherapy from Precigen Inc. (NASDAQ:PGEN) to treat a rare respiratory disease and whether the decision will set a precedent of more flexibility for rare disease therapies. They then take stock of recent translational coverage in BioCentury, including a report by Denali Therapeutics Inc. (NASDAQ: DNLI) of a way to avoid a key safety issue of anti-amyloid-targeting mAbs.

BioCentury’s Grand Rounds — Europe will take place in Cambridge, U.K., Sept. 17-19. The conference seeks to bridge academia, industry and investors for breakthrough innovation.